17e_JJ GROUP_NNP BALANCE_NNP SHEET_NNP At_IN 31_CD December_NNP Stock_NNP 2002 2001 2002_CD is_VBZ the_DT first_JJ year_NN that_IN Acambis_NNP Notes_NNP 000_CD 000_CD has_VBZ recognized_VBN stock_NN on_IN the_DT balance_NN Fixed_VBN assets_NNS sheet_NN ._.
This_DT largely_RB reflects_VBZ work-inIntangible_JJ assets_NNS :_: goodwill_NN 12_CD 13,641_CD 14,845_CD progress_NN and_CC finished_VBD goods_NNS under_IN Tangible_JJ assets_NNS 13_CD 19,988_CD 12,255_CD the_DT second_JJ CDC_NNP smallpox_NN vaccine_NN Investment_NN in_IN joint_JJ ventures_NNS :_: 14_CD contract_NN ._.
share_NN of_IN gross_JJ assets_NNS -_: 915_CD share_NN of_IN gross_JJ liabilities_NNS -_: 848_SYM -_: 67_CD Debtors_NNS :_: amounts_NNS receivable_NN within_IN Other_JJ investments_NNS 14_CD 1,100_CD 1,640_CD one_CD year_NN 34,729_CD 28,807_CD This_DT includes_VBZ amounts_NNS invoiced_VBD but_CC Current_JJ assets_NNS not_RB received_VBD at_IN the_DT year-end_NN of_IN Stock_NNP 15_CD 48,343_CD -_: 46.1_CD m_NN ,_, principally_RB from_IN the_DT CDC_NNP ._.
Debtors_NNS :_: amounts_NNS receivable_NN within_IN one_CD year_NN 16_CD 54,040_CD 7,542_CD Debtors_NNS :_: amounts_NNS receivable_NN after_IN one_CD year_NN 17_CD 4,925_CD 6,235_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN Short-term_JJ investments_NNS 105_CD 120_CD Cash_NN at_IN the_DT year-end_NN was_VBD 11.7_CD m._FW Cash_NN at_IN bank_NN and_CC in_IN hand_NN 11,672_CD 22,093_CD We_PRP received_VBD two_CD significant_JJ payments_NNS 119,085_CD 35,990_CD two_CD days_NNS after_IN the_DT year-end_NN which_WDT ,_, Creditors_NNPS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 18_CD 88,460_CD 16,603_CD had_VBD they_PRP been_VBN received_VBN two_CD days_NNS Net_JJ current_JJ assets_NNS 30,625_CD 19,387_CD earlier_JJR ,_, would_MD have_VB increased_VBN the_DT cash_NN Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 65,354_CD 48,194_CD position_NN significantly_RB ._.
These_DT large_JJ post_NN Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN one_CD year_NN 19_CD 18,897_CD 20,534_CD year-end_NN receipts_NNS are_VBP reflected_VBN Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS in_IN the_DT large_JJ debtors_NNS balance_NN at_IN Investment_NN in_IN joint_JJ ventures_NNS :_: 14_CD d_SYM 31_CD December_NNP 2002_CD of_IN 59.0_CD m._JJ share_NN of_IN assets_NNS 941_CD -_: share_NN of_IN liabilities_NNS 1,147_CD -_: We_PRP expect_VBP to_TO have_VB over_IN 100m_CD in_IN cash_NN 206_CD -_: Net_JJ assets_NNS 46,251_CD 27,660_CD by_IN the_DT end_NN of_IN 2003_CD ._.
Capital_NN and_CC reserves_NNS Creditors_NNS :_: amounts_NNS falling_VBG due_JJ Called-up_JJ share_NN capital_NN 21_CD 9,901_CD 9,308_CD within_IN one_CD year_NN Share_NN premium_NN account_NN 22_CD 87,745_CD 80,598_CD The_DT increase_NN in_IN trade_NN creditors_NNS and_CC Profit_NN and_CC loss_NN account_NN 22_CD 51,395_CD 62,246_CD deferred_VBN revenue_NN has_VBZ arisen_VBN Shareholders_NNS funds_NNS all_DT equity_NN 23_CD 46,251_CD 27,660_CD principally_RB from_IN the_DT second_JJ CDC_NNP smallpox_NN vaccine_NN contract_NN ._.
The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN this_DT Group_NNP balance_NN sheet_NN ._.
THE_DT INFORMATION_NN CONTAINED_VBD IN_IN THIS_NNP COLUMN_NNP HAS_VBZ NOT_RB BEEN_JJ AUDITED_NN ._.
